ntial functions including attention, mood, metabolism and respiration. Oveporexton (TAK-861) is the lead investigational orexin receptor 2 (OX2R) agonist asset in Takeda’s orexin franchise and received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in narcolepsy type 1 (NT1) from the U.S. Food and Drug Administration and the Center for Drug Evaluation of China’s National Medical Products Administration. The company is also investigating other orexin agonists in populations with orexin levels in the normal range, including TAK-360, an oral OX2R agonist initially being investigated for the treatment of narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) in Phase 2 studies, and other potential indications where orexin signaling is implicated. Additional preclinical assets are also in development including TAK-495, which is expected to enter the clinic in fiscal year 2025.

About Takeda

Takeda is focused on creating bet
=*=*=*=*=*=
当前为第10/18页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页